This early-phase trial tests whether combining niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy) can shrink or control recurrent or persistent uterine serous carcinoma. The study enrolled 8 adults whose cancer returned after standard chemotherapy. The goal is to see…
Phase: PHASE2 • Sponsor: Casey Cosgrove • Aim: Disease control
Last updated May 26, 2026 12:03 UTC